News articles about Horizon Therapeutics (NASDAQ:HPTX) have been trending somewhat positive recently, Accern Sentiment reports. The research firm rates the sentiment of news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Horizon Therapeutics earned a daily sentiment score of 0.14 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 45.9371102344929 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
NASDAQ:HPTX opened at $45.99 on Wednesday. Horizon Therapeutics has a 52 week low of $20.23 and a 52 week high of $46.96.
About Horizon Therapeutics
Horizon Therapeutics, Inc, formerly Hyperion Therapeutics, Inc, is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat disorders in the areas of orphan diseases. The Company’s products include RAVICTI (glycerol phenylbutyrate) oral liquid, BUPHENYL and AMMONAPS (sodium phenylbutyrate) tablets and powder.
Receive News & Ratings for Horizon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.